Type 2 Diabetes Mellitus As a Possible Risk Factor for Myasthenia Gravis: a Case-control Study

Overview

Journal Front Neurol

Specialty Neurology

Date 2023 May 4

PMID 37139075

Authors

Yu-Dong Liu

Fang Tang

Xiao-Li Li

Ya-Fei Liu

Peng Zhang

Chun-Lin Yang

Tong Du

Heng Li

Cong-Cong Wang

Ying Liu

Bing Yang

Rui-Sheng Duan

Affiliations

Soon will be listed here.

Abstract

Background: A certain number of myasthenia gravis (MG) patients clinically had type 2 diabetes mellitus (T2DM) prior to MG onset, which suggests that the onset of MG may correlate with the history of T2DM. This study aimed to examine the correlation between MG and T2DM.

Methods: In a single-center, retrospective, 1:5 matched case-control study, all 118 hospitalized patients with a diagnosis of MG from 8 August 2014 to 22 January 2019 were enrolled. In total, four datasets with different sources of the control group were retrieved from the electronic medical records (EMRs). Data were collected at the individual level. A conditional logistic regression analysis was used to test the risk of MG associated with T2DM.

Findings: The risk of MG was significantly associated with T2DM, and there were notable differences by sex and age. Whether compared to the general population, general hospitalized patients without autoimmune diseases (AIDs), or patients with other AIDs except MG, women aged over 50 years with T2DM had an increased risk of MG. The mean onset age of diabetic MG patients was more than that of the non-diabetic MG patients.

Interpretation: This study demonstrates that T2DM is strongly associated with the subsequent risk of MG and varies significantly by sex and age. It reveals that diabetic MG may be a unique subtype that is different from the conventional MG subgroup classification. More clinical and immunological features of diabetic MG patients need to be explored in further studies.

Citing Articles

Diabetes mellitus in patients with myasthenia gravis: a systematic review and meta-analysis.

Shao T, Lu J, Kang H, Zhang Y, Lan T, Wang J Endocrine. 2024; .

PMID: 39729181 DOI: 10.1007/s12020-024-04143-1.

Causal relationship between the immune phenotype of monocytes and myasthenia gravis: A Mendelian randomization study.

Dong J, Duan R, Zhang P Heliyon. 2024; 10(5):e26741.

PMID: 38449651 PMC: 10915380. DOI: 10.1016/j.heliyon.2024.e26741.

References

Zivkovic S, Clemens P, Lacomis D . Characteristics of late-onset myasthenia gravis. J Neurol. 2012; 259(10):2167-71. DOI: 10.1007/s00415-012-6478-6. View

Sakai W, Matsui N, Ishida M, Furukawa T, Miyazaki Y, Fujita K . Late-onset myasthenia gravis is predisposed to become generalized in the elderly. eNeurologicalSci. 2018; 2:17-20. PMC: 5818137. DOI: 10.1016/j.ensci.2016.02.004. View

Evoli A, Minisci C, Di Schino C, Marsili F, Punzi C, Batocchi A . Thymoma in patients with MG: characteristics and long-term outcome. Neurology. 2002; 59(12):1844-50. DOI: 10.1212/01.wnl.0000032502.89361.0c. View

Fan L, Ma S, Yang Y, Yan Z, Li J, Li Z . Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurol Res. 2018; 41(1):45-51. DOI: 10.1080/01616412.2018.1525121. View

Li L, Guan Y, Lu F, Song Y, Xu X, Jiang Y . [Glucose and lipid metabolic disorders in myasthenia gravis patients and its mechanisms]. Zhonghua Yi Xue Za Zhi. 2018; 98(8):581-586. DOI: 10.3760/cma.j.issn.0376-2491.2018.08.005. View

Pasnoor M, Dimachkie M, Farmakidis C, Barohn R . Diagnosis of Myasthenia Gravis. Neurol Clin. 2018; 36(2):261-274. DOI: 10.1016/j.ncl.2018.01.010. View

Mu L, Zhang Y, Sun B, Wang J, Xie X, Li N . Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. Clin Immunol. 2011; 141(1):36-48. DOI: 10.1016/j.clim.2011.04.013. View

Rodriguez Cruz P, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S . Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol. 2015; 72(6):642-9. PMC: 6044422. DOI: 10.1001/jamaneurol.2015.0203. View

Zhong H, Zhao C, Luo S . HLA in myasthenia gravis: From superficial correlation to underlying mechanism. Autoimmun Rev. 2019; 18(9):102349. DOI: 10.1016/j.autrev.2019.102349. View

10.

Lawlor D, Ebrahim S, Davey Smith G . The association between components of adult height and Type II diabetes and insulin resistance: British Women's Heart and Health Study. Diabetologia. 2002; 45(8):1097-106. DOI: 10.1007/s00125-002-0887-5. View

11.

Meriggioli M, Sanders D . Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5):475-90. PMC: 2730933. DOI: 10.1016/S1474-4422(09)70063-8. View

12.

Aarli J . Myasthenia gravis in the elderly: Is it different?. Ann N Y Acad Sci. 2008; 1132:238-43. DOI: 10.1196/annals.1405.040. View

13.

Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y . Sex-based differences in autoimmune diseases. Ann Ist Super Sanita. 2016; 52(2):205-12. DOI: 10.4415/ANN_16_02_12. View

14.

Shi B, Du X, Wang Q, Chen Y, Zhang X . Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. Metabolism. 2013; 62(6):778-85. DOI: 10.1016/j.metabol.2012.12.005. View

15.

Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M . The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?. Mod Pathol. 2006; 19(11):1437-45. DOI: 10.1038/modpathol.3800661. View

16.

Hong Y, Li H, Skeie G, Romi F, Hao H, Zhang X . Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients. J Neuroimmunol. 2016; 298:51-7. DOI: 10.1016/j.jneuroim.2016.07.001. View

17.

Li T, Yang C, Du T, Zhang P, Zhou Y, Li X . Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells. Clin Immunol. 2022; 245:109141. DOI: 10.1016/j.clim.2022.109141. View

18.

Smoak M, Pearce H, Mikos A . Microfluidic devices for disease modeling in muscle tissue. Biomaterials. 2018; 198:250-258. PMC: 6395563. DOI: 10.1016/j.biomaterials.2018.08.059. View

19.

Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q . Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017; 317(24):2515-2523. PMC: 5815077. DOI: 10.1001/jama.2017.7596. View

20.

Hennekens C, DeMets D . Statistical association and causation: contributions of different types of evidence. JAMA. 2011; 305(11):1134-5. DOI: 10.1001/jama.2011.322. View